摘要
自2019年末SARS-CoV-2病毒引起的新冠疫情COVID-19 (也称为2019-nCoV)暴发以来,快速传播,席卷全球。除了研发有效疫苗,迫切需要寻找安全有效的抗新冠病毒药物来对抗这种疾病。FDA紧急授权的paxlovid、molnupiravir、sotrovimab和bebtelovimab被证明对Omicron有效。本文综述了3年来全球对该病毒有效的抑制剂,包含受体抑制剂、抗体、天然产物抑制剂、合成抑制剂及临床上对其他RNA病毒有效的广谱抗病毒药物的研发进展。
Since the outbreak of the novel coronavirus(SARS-CoV-2) disease COVID-19(also known as 2019-nCoV) caused by SARS-CoV-2 in the end of 2019,it has spread rapidly in worldwide.Besides developing effective vaccines,it is urgent to develop safe and effective anti-SARS-CoV-2 drugs to fight this disease.Paxlovid,molnupiravir,sotrovimab and bebtelovimab are urgently authorized by FDA have been proved to be effective against Omicron.This manuscript mainly reviews the recent progress of effective inhibitors against the virus in the world,including receptor inhibitors,antibodies,natural product inhibitors,synthetic inhibitors and broad-spectrum antiviral drugs that are effective against other RNA viruses.
作者
林梨萍
唐飞
许瑞安
崔秀灵
LIN Li-ping;TANG Fei;XU Rui-an;CUI Xiu-ling(Engineering Research Center of the Ministry of Education for Molecular Drugs,Fujian Key Laboratory of Molecular Medicine,Fujian Key Laboratory of Precision Medicine and Molecular Diagnosis,Xiamen Key Laboratory of Marine and Genetic Drugs,College of Biomedicine,Huaqiao University,Xiamen 361021,China;Xiamen Center for Disease Control and Prevention,Xiamen 361021,China)
出处
《药学学报》
CAS
CSCD
北大核心
2023年第1期39-51,共13页
Acta Pharmaceutica Sinica
基金
福建省创新药物与创新技术产业化(3502ZCQXT2021006)
泉州市抗新型冠状病毒感染肺炎药物筛选(2020SY003)
教育部111创新引智基地(BC2018061)。
